Organoids of liver diseases: From bench to bedside

doi:10.3748/wjg.v25.i16.1913

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 16

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (13134)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series.

Item

Count

PDF

953

WORD

213

HTML

9583

Figures (1-4)

570

Sum=11319

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

727

Download

1088

Sum=1815

Apr 28, 2019 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Apr 28, 2019; 25(16): 1913-1927
Published online Apr 28, 2019. doi: 10.3748/wjg.v25.i16.1913

Full Size Figure Download Figure

Figure 1 Culture of liver organoids in vitro. A: Liver organoids cultured from pluripotent stem cells (PSCs). Somatic cells are reprogrammed into induced PSCs; epidermal growth factor (EGF), fibroblast growth factor 2 (FGF2), and other substances are added to the medium; and the cells are cultured on Matrigel to form liver organoids; B: Liver organoids cultured from adult stem cells. Lgr5⁺ cells are isolated by fluorescence-activated cell sorting, and Wnt3a, Y27632, EGF, Rspo1, FGF, and other substances are added to form organoids by 3D culture. FACS: Fluorescence-activated cell sorting; iPSCs: Induced pluripotent stem cells; FGF2: Fibroblast growth factor 2; EGF: Epidermal growth factor.

Citation: Wu LJ, Chen ZY, Wang Y, Zhao JG, Xie XZ, Chen G. Organoids of liver diseases: From bench to bedside. World J Gastroenterol 2019; 25(16): 1913-1927
URL: https://www.wjgnet.com/1007-9327/full/v25/i16/1913.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i16.1913